Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Abramson, Jeremy S; Ku, Matthew; Hertzberg, Mark; Huang, Hui-Qiang; Fox, Christopher P; Zhang, Huilai; Yoon, Dok Hyun; Kim, Won-Seog; Abdulhaq, Haifaa; Townsend, William; Herbaux, Charles; Zaucha, Jan M; Zhang, Qing-Yuan; Chang, Hung; Liu, Yanyan; Cheah, Chan Yoon; Ghesquieres, Herve; Simko, Stephen; Orellana-Noia, Victor; Ta, Richard; Relf, James; Dixon, Mark; Kallemeijn, Martine; Mulvihill, Estefania; Huang, Huang; Lundberg, Linda; Gregory, Gareth P

doi:10.1016/s0140-6736(24)01774-4

The Lancet

2024

DOI: 10.1016/s0140-6736(24)01774-4

|View full text |Cite

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S Abramson,

Matthew Ku,

Mark Hertzberg

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Cited by 3 publications

References 33 publications

Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection

Bispecific antibodies for the treatment of hematologic malignancies: The magic is T-cell redirection

Glofit-GemOx: a new treatment paradigm in relapsed or refractory diffuse large B-cell lymphoma?

Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL

Contact Info

Product

Resources

About